The guide to
Monoclonal Antibodies for Alzheimer's disease
What are monoclonal antibodies?
What mab drugs are available today?
Mab drugs and brain bleeds
What are monoclonal antibodies?
Monoclonal antibody drugs (or 'mab' in short) are used to treat many diseases, including cancer. It binds to a single antigen, and can be used alone or as delivery vehicles to carry other substances to the cells they’re searching for. Some mab drugs are considered immunotherapies, because they help the immune system recognize and destroy certain target cells.
What are they?
They are man-made immune cells that power drugs to treat cancer, osteoporosis, and other disorders.
What do they do?
They target and destroy foreign viruses, bacteria, plaques, or other unwanted pathogens in the body.
What are monoclonal antibodies?
Why are they called "mab drugs"?
Generic names of monoclonal antibodies often end in “mab”, such as trastuzumab, rituximab, and lecanemab.
How mab drugs fight Alzheimer’s
These Alzheimer’s anti-amyloid mab drugs prevent the buildup of amyloid plaques between brain cells.Both Leqembi and Kisunla attach to plaques. Leqembi also attaches to some forms of beta-amyloid before they become plaques.
Amyloid plaques block the communication among neural circuits and weaken brain function.
By seeking and binding to the plaques, monoclonal antibodies help clear them out of the brain.
Alzheimer’s mab drugs on the market
Mab drugs on whole are still early in development, Experts say they show promise in slowing early-stage Alzheimer's. As of July 2024, only Leqembi (lecanemab) and Kisunla (donanemab) have been approved as a treatment for Alzheimer’s.
*CDR-SB: Clinical Dementia Rating–Sum of Boxes scale.
A higher score indicates more impairment.
Mab drugs and brain bleeds
One side effect of Leqembi and Kisunla is brain bleeds, also called amyloid-related imaging abnormalities (ARIA). These tiny brain hemorrhages are typically so small they're asymptomatic and go undetected. However, in rare cases, they can be serious. Individuals with the APOE4 gene have higher risk of bleeding due to higher accumulations of amyloid in their brains.
Read more
The future of mab drugs for Alzheimer’s
The latest real world data on people taking Leqembi shows that it's safe and well-managed.
More data
As more people take mab drugs, scientists will gather long-term data to better understand their side effects and efficacy.
More access
So far, these drugs have been hard to get, in large part due to their format. Making these originally infusion-based Alzheimer’s mab drugs available in new formats, like pills, will help expand accessibility.
Read more about mab drug Research
Learn more about Alzheimer’s mab drugs
Click the links below to read Being Patient's coverage on the latest -mab drugs.
Leqembi (FDA-approved July 6, 2023)
Kisunla (FDA-approved July 2, 2024)
Want to learn more?
Visit
beingpatient.com
for the latest news and information on brain health and Alzheimer's disease
Return
MOBILE DRAFT - Monoclonal Antibodies
Deborah Kan
Created on March 2, 2026
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Project Roadmap Timeline
View
Step-by-Step Timeline: How to Develop an Idea
View
Artificial Intelligence History Timeline
View
Practical Timeline
View
History Timeline
View
Education Timeline
View
Timeline video mobile
Explore all templates
Transcript
The guide to
Monoclonal Antibodies for Alzheimer's disease
What are monoclonal antibodies?
What mab drugs are available today?
Mab drugs and brain bleeds
What are monoclonal antibodies?
Monoclonal antibody drugs (or 'mab' in short) are used to treat many diseases, including cancer. It binds to a single antigen, and can be used alone or as delivery vehicles to carry other substances to the cells they’re searching for. Some mab drugs are considered immunotherapies, because they help the immune system recognize and destroy certain target cells.
What are they?
They are man-made immune cells that power drugs to treat cancer, osteoporosis, and other disorders.
What do they do?
They target and destroy foreign viruses, bacteria, plaques, or other unwanted pathogens in the body.
What are monoclonal antibodies?
Why are they called "mab drugs"?
Generic names of monoclonal antibodies often end in “mab”, such as trastuzumab, rituximab, and lecanemab.
How mab drugs fight Alzheimer’s
These Alzheimer’s anti-amyloid mab drugs prevent the buildup of amyloid plaques between brain cells.Both Leqembi and Kisunla attach to plaques. Leqembi also attaches to some forms of beta-amyloid before they become plaques.
Amyloid plaques block the communication among neural circuits and weaken brain function.
By seeking and binding to the plaques, monoclonal antibodies help clear them out of the brain.
Alzheimer’s mab drugs on the market
Mab drugs on whole are still early in development, Experts say they show promise in slowing early-stage Alzheimer's. As of July 2024, only Leqembi (lecanemab) and Kisunla (donanemab) have been approved as a treatment for Alzheimer’s.
*CDR-SB: Clinical Dementia Rating–Sum of Boxes scale. A higher score indicates more impairment.
Mab drugs and brain bleeds
One side effect of Leqembi and Kisunla is brain bleeds, also called amyloid-related imaging abnormalities (ARIA). These tiny brain hemorrhages are typically so small they're asymptomatic and go undetected. However, in rare cases, they can be serious. Individuals with the APOE4 gene have higher risk of bleeding due to higher accumulations of amyloid in their brains.
Read more
The future of mab drugs for Alzheimer’s
The latest real world data on people taking Leqembi shows that it's safe and well-managed.
More data
As more people take mab drugs, scientists will gather long-term data to better understand their side effects and efficacy.
More access
So far, these drugs have been hard to get, in large part due to their format. Making these originally infusion-based Alzheimer’s mab drugs available in new formats, like pills, will help expand accessibility.
Read more about mab drug Research
Learn more about Alzheimer’s mab drugs
Click the links below to read Being Patient's coverage on the latest -mab drugs.
Leqembi (FDA-approved July 6, 2023)
Kisunla (FDA-approved July 2, 2024)
Want to learn more?
Visit
beingpatient.com
for the latest news and information on brain health and Alzheimer's disease
Return